• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Allergan files "potential merger transaction" with SEC

Quote




Rob Harris, Tribute's President and Chief Executive Officer, commented, "This fourth patent further expands the scope of Tribute's exclusive rights in the United States for Uracyst®, and further validates the innovative nature of Tribute's approach to the treatment of IC/BPS." Mr. Harris further stated, "The Company has currently accelerated plans to maximize the value of this unique product in the U.S. market especially when considering other recent M&A transactions in this market."
 




























Actavis bought Warner Chilcott and laid everyone off... Actavis bought Forest and FOREST MGMT laid people off (mostly Actavis people)...

So what will happen? Allergan would be at the mercy of FOREST MGMT and how you fit into their structure. Good luck.
 




Seriously. The only difference between Actavis and Valeant is the number of donuts in the executive suite breakfast service.

The idea that Actavis is a white knight is laughable. Wolf in sheep's clothing to keep the masses docile while the rug gets pulled out from under us.

Where has Brent Saunders ever been involved in M&A activity and not taken 30% of headcount away? Answer, nowhere
 




Anonymous said:
What about Denderon?
Click to expand...

Dendreon Corp. (DNDN) plunged almost 81% after the company along with its U.S. subsidiaries filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on Nov 10, 2014.

Dendreon also announced that it has reached an agreement with certain holders representing approximately 84% of the $620 million of the aggregate principal amount of the company's 2.875% Convertible Senior Notes due 2016. As per the terms of the agreement, Dendreon will undergo a severe financial restructuring, which may take the form of a stand-alone recapitalization, sales of its assets or even a sale of the company. During this process the company’s prostate cancer drug, Provenge, is expected to remain commercially available.
 








Anonymous said:
Dendreon Corp. (DNDN) plunged almost 81% after the company along with its U.S. subsidiaries filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on Nov 10, 2014.

Dendreon also announced that it has reached an agreement with certain holders representing approximately 84% of the $620 million of the aggregate principal amount of the company's 2.875% Convertible Senior Notes due 2016. As per the terms of the agreement, Dendreon will undergo a severe financial restructuring, which may take the form of a stand-alone recapitalization, sales of its assets or even a sale of the company. During this process the company’s prostate cancer drug, Provenge, is expected to remain commercially available.
Click to expand...

Take out the word "Dendreon" and replace with the word "Valeant", and change the bankruptcy filing year from 2014 to 2016.
 




Anonymous said:
Seriously. The only difference between Actavis and Valeant is the number of donuts in the executive suite breakfast service.

The idea that Actavis is a white knight is laughable. Wolf in sheep's clothing to keep the masses docile while the rug gets pulled out from under us.

Where has Brent Saunders ever been involved in M&A activity and not taken 30% of headcount away? Answer, nowhere
Click to expand...

The obvious synergies will be in corporate. Brent believes in D (not R&D) so more cuts there. Not sure how the combined sales force shakes out.
 












Actavis Said in Talks to Acquire Allergan for Over $60 Billion

By David Welch, Jeffrey McCracken and Ruth David Nov 12, 2014 10:19 AM ET 0

Nov. 12 (Bloomberg) -- Reports link Actavis to talks with Allergan on an acquisition that could be worth more than $60 billion dollars. Bloomberg’s Jeff McCracken breaks down the potential deal, how it got to this point and the players involved on “Market Makers.”

Actavis Plc is in talks to acquire Allergan Inc. for at least $60 billion, or more than $200 a share, with a possible agreement as little as two weeks away, said people with knowledge of the matter.

The two companies are trying to narrow a gap of about $3 billion between what Actavis wants to pay and what Allergan is asking for, said two of the people, asking not to be identified discussing private information. The maker of anti-wrinkle treatment Botox is seeking more than $210 a share while Actavis wants to pay closer to $200, said two of the people.

Any offer from Actavis will likely include its own shares as well as cash, the people said. Irvine, California-based Allergan rose 1.3 percent to $197.85 a share as of 10:08 a.m. in New York today, giving the company a market value of about $59 billion.

The companies may be able to reach a deal this month, the people said, as Allergan seeks to fend off a hostile bid from Valeant Pharmaceuticals International Inc. Valeant has said it’s willing to pay at least $200 a share for Allergan and has the backing of Allergan’s largest shareholder - activist investor Bill Ackman’s Pershing Square Capital Management LP.

Although the talks could drag on, and there’s no certainty that the two sides will reach an agreement, Allergan is trying to strike a deal before an investor meeting on Dec. 18, the people said. That’s when shareholders will vote on Valeant and Ackman’s proposal to remove Allergan directors, with a plan to eventually replace them with those who are more amenable to Valeant’s offer.

“Grossly Inadequate”

Allergan has described Valeant’s offers as “grossly inadequate” and argued the Canadian company would gut its research and development budget and use its cash flow to pay down debt accumulated from previous acquisitions.

Allergan spokeswoman Bonnie Jacobs declined to comment as did David Belian, a spokesman for Actavis.

Actavis gained 0.4 percent to $244.64, giving it a market value of about $65 billion, while Laval, Quebec-based Valeant was unchanged. Valeant’s market cap is closer to $43 billion.

Valeant set the low end of the bidding at about $200 a share when the company said on Oct. 27 that it is willing to bump its cash and stock offer -- currently valued at about $180 a share -- to that amount.

Allergan today announced amendments to its bylaws, making it easier for shareholders to call a special meeting. Ackman had accused the Botox maker of having overly complicated bylaws that made it hard to call a shareholder meeting, now scheduled for Dec. 18.
 




Anonymous said:
Seriously. The only difference between Actavis and Valeant is the number of donuts in the executive suite breakfast service.

The idea that Actavis is a white knight is laughable. Wolf in sheep's clothing to keep the masses docile while the rug gets pulled out from under us.

Where has Brent Saunders ever been involved in M&A activity and not taken 30% of headcount away? Answer, nowhere
Click to expand...

Ignorant troll. Missing the point.
 




Top Bottom
Back
Quote